Enantia
About Enantia
Enantia is a Chemicals & Materials company, and was acquired by Inveready in February 2025. Medicinal chemistry and solid-state RD services are offered by Enantia. Its focus areas include Chemicals and Materials and Chemical Services.
Company details
Contract research and development services are delivered by Enantia within the pharmaceutical industry, with emphasis on medicinal chemistry and solid-state forms. Expertise encompasses small molecule design, asymmetric synthesis, cocrystal development, and analytical methods. Challenges in chemical synthesis are addressed, including route optimization, impurity analysis, and solid form characterization. Performance testing and handling of potent compounds are included in the scope of operations.
- Stage Acquired
- SectorsChemicals & Materials
- Website enantia.com
- Social LinkedIn
- Acquired by Inveready (Feb 2025)
- Legal Name Enantia
Investors in Enantia
Enantia has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Inveready.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Inveready is recognized as a leading Spanish financial services firm. | 2008 | inveready.com | San Sebastián, Spain |
Investor details for Enantia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Enantia
Contract research and development services are delivered by Enantia within the pharmaceutical industry, with emphasis on medicinal chemistry and solid-state forms. Expertise encompasses small molecule design, asymmetric synthesis, cocrystal development, and analytical methods. Challenges in chemical synthesis are addressed, including route optimization, impurity analysis, and solid form characterization. Performance testing and handling of potent compounds are included in the scope of operations.
Enantia has 1 investor. Key investors include Inveready.
Enantia operates through Enantia.
Yes. Enantia was acquired by Inveready in February 2025.